Oprelvekin
| Clinical data | |
|---|---|
| AHFS/Drugs.com | Monograph |
| Routes of administration | subcutaneous (s.c.) injection |
| ATC code | |
| Legal status | |
| Legal status |
|
| Pharmacokinetic data | |
| Bioavailability | >80% (s.c.) |
| Metabolism | mainly renal |
| Elimination half-life | 6.9 ± 1.7 hours |
| Identifiers | |
| CAS Number | |
| IUPHAR/BPS | |
| DrugBank | |
| ChemSpider |
|
| UNII | |
| ChEMBL | |
| Chemical and physical data | |
| Formula | C854H1411N253O235S2 |
| Molar mass | 19047.34 g·mol−1 |
| (what is this?) (verify) | |
Oprelvekin is recombinant interleukin eleven (IL-11), a thrombopoietic growth factor that directly stimulates the proliferation of hematopoietic stem cells and megakaryocyte progenitor cells and induces megakaryocyte maturation resulting in increased platelet production. It is marketed under the trade name Neumega.